Clinical Evidence: What UK Weight Loss Trials Actually Show
Key Differences Between Wegovy And Mounjaro Mechanisms
The primary difference between Wegovy and Mounjaro lies in their active ingredients and hormone targets. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural incretin hormone GLP-1, which signals satiety to the brain after meals. Mounjaro contains tirzepatide, which activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, creating a dual hormone approach to appetite regulation.
Both prescription-only medicines require weekly injections and work best alongside a reduced-calorie diet and increased physical activity. The difference between Wegovy and Mounjaro dosing schedules also varies, with Wegovy following a structured 20-week escalation to 2.4mg maintenance, whilst Mounjaro escalates over 12 weeks to 15mg maximum. UK patients can access both treatments through our GPhC-registered pharmacy following clinical assessment.
Wegovy vs Mounjaro Pricing And UK Availability
Understanding the cost difference between Wegovy and Mounjaro helps UK patients plan their weight management investment. Wegovy starter doses begin at £79.99 for 0.25mg (weeks 1-4) after applying code FIRST40, progressing to £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the 2.4mg maintenance dose. Our Getting Started bundles provide convenient dose progression, such as the Intro Duo (0.25mg & 0.5mg) for £169.99.
Returning customers benefit from the DOSE25 discount code applied at checkout, with these being the final prices customers pay for genuine, MHRA-approved medication. The difference between Wegovy and Mounjaro costs reflects their distinct manufacturing processes and clinical development investments. EverydayMeds stocks both treatments with next-day delivery once prescribed, ensuring continuous treatment availability across the UK.
Clinical Trial Evidence: Wegovy Weight Loss Results
The landmark STEP clinical trials demonstrate substantial weight management outcomes for Wegovy users. In STEP 1, patients taking Wegovy alongside lifestyle interventions achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). STEP 5 confirmed sustainability with clinically studied weight loss maintained at 2 years.
The difference between Wegovy and Mounjaro trial designs prevents direct comparison of weight loss percentages, as they involved different patient populations and study protocols. STEP 3 showed enhanced results (~16%) when Wegovy was combined with intensive behavioural therapy, highlighting the importance of comprehensive lifestyle support alongside medication.
How Wegovy Works For Weight Management
Wegovy's semaglutide targets GLP-1 receptors in the brain's appetite control centres, specifically the hypothalamus and brainstem regions responsible for hunger and satiety signalling. When injected weekly, it slows gastric emptying, meaning food stays in the stomach longer, promoting feelings of fullness after smaller portions. The medication also reduces food cravings by modulating reward pathways associated with high-calorie food preferences. This dual action on both physiological hunger and psychological food desires helps patients naturally reduce caloric intake without the intense hunger often experienced with traditional calorie restriction. The FlexTouch pen delivery system ensures consistent drug absorption for optimal therapeutic effect.
UK Ordering Process For Weight Loss Medication
Accessing the difference between Wegovy and Mounjaro through EverydayMeds begins with our 3-minute online clinical assessment, covering medical history, current medications, and weight management goals. Our UK-qualified prescribers review applications within 3 working days (express 24-hour service available), ensuring safe prescribing based on NICE TA875 guidelines for weight management medication. Once approved, medications are dispatched via next-day cold-chain delivery, maintaining the 2-8°C temperature requirement throughout transit. The prescription-only nature of both treatments ensures clinical oversight, with prescribers available for ongoing support throughout your weight management journey. Payment is secured through encrypted systems, with discount codes applied automatically at checkout.
Storage And Practical Considerations
A key practical difference between Wegovy and Mounjaro involves storage flexibility during travel or routine disruptions. Wegovy pens maintain potency for 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day limit, making Wegovy more suitable for extended travel or flexible storage needs. Both require refrigeration at 2-8°C before first use, with the FlexTouch pen system providing accurate dose delivery throughout the temperature-controlled storage period. The weekly injection schedule for both treatments requires consistent timing, ideally on the same day each week, with dose escalation mandatory to minimise gastrointestinal side effects. Proper disposal through pharmacy return schemes ensures safe handling of used injection devices.
Real-World UK Weight Loss Outcomes
Understanding the difference between Wegovy and Mounjaro extends beyond clinical trials to real-world UK patient experiences within the NHS and private healthcare settings. NICE TA875 approval reflects cost-effectiveness analysis specific to UK healthcare economics, with weight management services increasingly incorporating these treatments alongside psychological support and dietary counselling. Patient registries suggest similar tolerability profiles, though individual responses vary based on genetics, adherence, and lifestyle factor integration.
The cardiovascular benefits demonstrated in the SELECT trial (20% reduction in major adverse events) add significant value for UK patients with obesity-related comorbidities. Both treatments require long-term commitment, as STEP trial extensions show patients typically regain two-thirds of weight lost within one year of discontinuation, emphasising the chronic nature of obesity treatment.
Expert Guidance On Treatment Selection
Choosing between these prescription-only medicines requires personalised clinical assessment considering individual health profiles, treatment goals, and practical lifestyle factors. Our GPhC-registered pharmacy (#9012878) prescribers evaluate BMI criteria (≥30 or ≥27 with comorbidities), previous weight loss attempts, medication interactions, and patient preferences regarding dosing schedules and storage requirements. The difference between Wegovy and Mounjaro may influence selection based on specific patient needs, such as travel requirements favouring Wegovy's extended room temperature stability. Both treatments are available through EverydayMeds with comprehensive prescriber support, ensuring optimal treatment matching for sustainable weight management success. Apply discount codes FIRST40 (new patients) or DOSE25 (returning patients) at checkout, with secure ordering available at https://everydaymeds.co.uk/collections/wegovy following clinical approval.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
